Nuvaxovid includes an engineered fragment of the spike protein itself—albeit one without the genetic material that causes actual disease. It’s not a totally new approach to vaccine design.

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

About Nuvaxovid™ (NVX-CoV2373) NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.

Nuvaxovid is supplied in a single-dose prefilled syringe containing 0.5mL suspension for intramuscular injection; it should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).

Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 vaccine, Spikevax, for use in children aged six months to 11 years, who ...

--Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has approved a ...

As for Nuvaxovid, this standalone Novavax Covid-19 vaccine received its FDA approval in May, a regulatory decision that covers its use in those age 65 and older.

Alas, Nuvaxovid didn't live up to its promise in the second quarter. During the period, Novavax reported total revenue of $185.9 million, for a substantial 37.6% year-over-year decline.

The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...

Nuvaxovid is also available for use as a booster in adults aged 18 and older in the U.S., European Union, Japan, Australia, New Zealand, Switzerland, and Israel. In addition, ...

While the company recorded $88.3M in revenue for Q4 with a ~70% YoY slump exceeding the consensus by ~3.9M, its product sales, driven by its Nuvaxovid COVID shot, plunged ~80% YoY to $50.1M.

GAITHERSBURG, Md., Dec. 7, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious ...